Lida A. Mina, MD, discusses the evolving role of ADCs across breast cancer subtypes, current data on the use of CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer, and the increased use of genomic testing and NGS to improve the sequencing of agents in triple-negative breast cancer.
Nusayba Bagegni, MD, details ongoing research and possibilities for the treatment landscape in the future, which includes investigating escalating approaches through more research in clinical trials.